Quality of life in patients with relapsing multiple sclerosis taking intramuscular interferon beta-1a (Avonex®)

被引：0
作者：
Hyde, R.
Rudick, R. A.
Foulds, P.
You, X.
机构：
[1] Biogen Idec Int, Zug, Switzerland
[2] Mellen Ctr Multiple Sclerosis Treatment & Res, Cleveland, OH USA
[3] Biogen Idec Inc, Cambridge, MA 02142 USA
来源：
JOURNAL OF NEUROLOGY | 2008年 / 255卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P455
引用
收藏
页码：113 / 113
页数：1
相关论文
共 50 条
[31]   Long-term follow-up of multiple sclerosis patients treated with interferon beta-1a (Avonex®) [J].
Vermersch, R ;
Denève, M ;
Waucquier, N ;
de Seze, J .
MULTIPLE SCLEROSIS, 2005, 11 :S75-S75
[32]   A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis [J].
Scott, Thomas ;
Shang, Shulian ;
Castrillo-Viguera, Carmen .
NEUROLOGY, 2017, 88
[33]   Interferon Beta-1a (AVONEX®) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study [J].
Kleinschnitz, Christoph ;
Niemczyk, Gabriele ;
Rehberg-Weber, Karin ;
Wernsdoerfer, Colin .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2015, 16 (07) :15271-15286
[34]   Neutralizing antibodies in multiple sclerosis patients on weekly intramuscular Avonex and biosimilar interferon beta-1a (CinnoVex): Comparing results of measurements in two different laboratories [J].
Shahkarami, Mohammad Amir ;
Vaziri, Behrouz ;
Salami, Shiva ;
Harandi, Ali Amini ;
Oger, Joel .
JOURNAL OF IMMUNOLOGICAL METHODS, 2013, 388 (1-2) :46-48
[35]   Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex) [J].
Cohan, Stanley L. ;
Hendin, Barry A. ;
Reder, Anthony T. ;
Smoot, Kyle ;
Avila, Robin ;
Mendoza, Jason P. ;
Weinstock-Guttman, Bianca .
CNS DRUGS, 2021, 35 (07) :743-767
[36]   Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis [J].
Guijarro, Cristina ;
Benito-Leon, Julian ;
Bermejo-Pareja, Felix .
NEUROLOGICAL SCIENCES, 2011, 32 (02) :309-311
[37]   Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex) [J].
Stanley L. Cohan ;
Barry A. Hendin ;
Anthony T. Reder ;
Kyle Smoot ;
Robin Avila ;
Jason P. Mendoza ;
Bianca Weinstock-Guttman .
CNS Drugs, 2021, 35 :743-767
[38]   Development of an electronic device for subcutaneous injection of interferon beta-1a in patients with relapsing multiple sclerosis [J].
Mikol, D. ;
Verdun, E. ;
Exell, S. ;
Devonshire, V. .
MULTIPLE SCLEROSIS, 2010, 16 (10) :1282-1282
[39]   Subgroup analyses from SENTINEL:: a randomized controlled trial of natalizumab (Tysabri®) and interferon beta-1a (AVONEX®) in relapsing multiple sclerosis (MS) [J].
Confavreux, C ;
Stuart, WH ;
Calabresi, PA ;
Galetta, SL ;
Radue, EW ;
Rudick, RA ;
Lublin, FD ;
Weinstock-Guttman, B ;
Wynn, DR ;
Lynn, F ;
Panzara, MA ;
Sandrock, AW .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2005, 238 :S72-S72
[40]   ECONOMIC IMPLICATIONS OF REPLACING INTERFERON BETA-1A WITH OCRELIZUMAB IN RELAPSING MULTIPLE SCLEROSIS [J].
Thomas, N. ;
Ma, E. ;
Yu, E. B. .
VALUE IN HEALTH, 2017, 20 (05) :A191-A191
12345